Arthex Biotech is a Spanish biopharmaceutical company, developing advanced RNA treatments against genetic diseases. The company’s therapeutic approach uses an antisense oligonucleotide (ASO) to inhibit micro RNA-23b, a key regulator for disease pathogenesis. By restoring deregulated protein levels in the muscle Arthex will provide a novel and disease modifying treatment option for patients with myotonic dystrophy.
